Zevra Therapeutics, Inc. Common Stock ZVRA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T16:01:19.171Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T16:00:58.138416879Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T16:01:17.209564+00:00
Zevra Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.86 | 144.0% | 26.5% | |||
| 25Δ | ||||||
| 30Δ | 10.52 | 250.3% | 21.6% | |||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 12.25 | 67.7% | 5.7% | |||
| 50Δ | 12.08 | 68.6% | 4.8% | 12.20 | 90.2% | 5.0% |
| 55Δ | 12.55 | 107.1% | 4.9% | |||
| 60Δ | 12.90 | 123.9% | 4.8% | |||
| 65Δ | 13.20 | 124.4% | 4.2% | |||
| 70Δ | 10.94 | 146.5% | 5.2% | 13.47 | 118.4% | 3.3% |
| 75Δ | 10.69 | 135.0% | 4.1% | 13.75 | 112.5% | 2.5% |
| 80Δ | 10.44 | 123.5% | 3.0% | 14.04 | 106.9% | 1.6% |
20Δ
- Pseudo strike
- 14.86
- IV
- 144.0%
- B/E move
- 26.5%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.52
- IV
- 250.3%
- B/E move
- 21.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 12.25
- IV
- 67.7%
- B/E move
- 5.7%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 12.08
- IV
- 68.6%
- B/E move
- 4.8%
- Pseudo strike
- 12.20
- IV
- 90.2%
- B/E move
- 5.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.55
- IV
- 107.1%
- B/E move
- 4.9%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.90
- IV
- 123.9%
- B/E move
- 4.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.20
- IV
- 124.4%
- B/E move
- 4.2%
70Δ
- Pseudo strike
- 10.94
- IV
- 146.5%
- B/E move
- 5.2%
- Pseudo strike
- 13.47
- IV
- 118.4%
- B/E move
- 3.3%
75Δ
- Pseudo strike
- 10.69
- IV
- 135.0%
- B/E move
- 4.1%
- Pseudo strike
- 13.75
- IV
- 112.5%
- B/E move
- 2.5%
80Δ
- Pseudo strike
- 10.44
- IV
- 123.5%
- B/E move
- 3.0%
- Pseudo strike
- 14.04
- IV
- 106.9%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 92.94% | |
| 86.10% | |
| 87.86% | |
| 91.80% | |
| 94.66% | |
| 89.17% | |
| 108.49% | |
| 76.57% | |
| 79.38% | |
| 84.43% |
Biotechnology
ZYME
Description unavailable
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →ABSI
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid…
More →